April 28, 2006 – Biomira reported positive survival data for Stimuvax, its treatment for lung cancer; FibroGen signed a monster deal with Astellas Pharma of Japan for the ex-US rights to its anemia drug; Genzyme received FDA approval of Myozyme as a Pompe disease therapy; Neurocrine announced its endometriosis drug successfully passed a Phase II proof-of-concept trial; Nastech said a Phase I trial of its Parathyroid Hormone nasal spray showed bioequivalence to the injection; Restore Medical set its IPO terms; Abbott Labs said European authorities recommended approval for Humira as a treatment for arthritis of the spine; Inhibitex will not put Veronate into another Phase III trial; and European regulators recommended the use of Tysabri for multiple sclerosis, if it is used as a single agent. The Centient Biotech 200™ traded 12 points higher to 3777.56, a rise of .31%. More details...
